Not Signed In - 48-Week Data On Investigational Antiretroviral TMC125 From Tibotec Pharmaceuticals Ltd
Sun, 20 Aug 2006 08:00 PM EST
... Toronto, Canada - Tibotec Pharmaceuticals Ltd. presented 48-week efficacy and safety data on TMC125, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) at the 16th Internationals AIDS conference (IAC), AIDS 2006, in Toronto, Canada, this week. TMC125 is currently being investigated in phase 3 trials (DUET 1 and 2) in treatment-experienced adult patients. [click link for full article] ...
Related Topics
- Data & Statistics
- Data Analysis
- National Data
- Fetal Development
- Pregnancy
- Mining
- National Women's Health Week
- Youth Violence
- Hollywood Diet
- Logging
- Chemical Safety
- Visualization
- Influenza Surveillance Data
- 6 Week Body Makeover
- Universal Data Collection Updates
- Hospital Data / Inpatient Care
- Vaccine Safety: Data-Sharing Process
- Sexual Health
- Safety
- Lifestyle
email this page
print this page
bookmark this page
feedback on this page
